Immunoexpression and Prognostic Significance of Multidrug Resistance Markers in Feline Mammary Carcinomas

Manoel, Verônica Correia; Carvalho, Pedro Luis Teles De; Govoni, Verônica Mollica; Silva, Tereza Cristina da; Queiroga, Felisbina L.; Cogliati, Bruno

doi:10.1016/j.jcpa.2020.12.008

Cited by 2 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, P-gp was expressed in 93.4% of FMC and was positively associated with tumour grade (P=0.049). metallothionein expression was significant in triple-negative basal-and normal-like molecular FMC subtypes (P=0.023) (Manoel et al, 2021).…”

Section: Introductionmentioning

confidence: 97%

Clinical evaluation of the effectiveness of meloxivet in the complex treatment of cats with mammary gland carcinoma

Bilyi,

Herhaulović

2024

Vet. stn. (Online)

View full text Add to dashboard Cite

This study presents the results of a clinical administration of meloxivet nonsteroidal anti-inflammatory treatment against the background of the docetaxel + cyclophosphamide regimen chemotherapy following bilateral mastectomy in cats with mammary gland carcinoma. The inclusion of meloxivet in complex chemotherapy against breast carcinomas bilateral mastectomy improved treatment results. In particular, survival was extended in the clinical stages: I and II - by 1.3 times, III - by 1.6 times, and the disease-free period was increased by 1.5, 1.4 and 1.9 times, respectively. Complex treatment of cats including non-steroidal anti-inflammatory therapy reduced the risk of disease progression depending on the clinical stage during the first six months after the end of the course. An increase in the number of patients with subsequent metastasis (after six to twelve months) was also noted. The use of meloxivet made it possible to avoid disease progression in cats up to three years of age, and to reduce its probability and delay the onset of metastasis in all age categories. The proposed scheme of treatment of cats with mammary gland carcinomas reduced side effects, indicating an insignificant risk of negative effects of long-term meloxivet use against the background of a 1.5- fold reduction in the frequency of recurrences in the surgical intervention area.

show abstract

Section: Introductionmentioning

confidence: 97%

Clinical evaluation of the effectiveness of meloxivet in the complex treatment of cats with mammary gland carcinoma

Bilyi,

Herhaulović

2024

Vet. stn. (Online)

View full text Add to dashboard Cite

show abstract

Comparison of MMP-2, MMP-9, COX-2, and PGP Expression in Feline Injection-Site and Feline Noninjection-Site Sarcomas—Pilot Study

Wojtkowska,

Małek,

Giziński

et al. 2024

Animals

View full text Add to dashboard Cite

Feline injection-site sarcomas (FISSs) are aggressive neoplasms that have been associated mostly with vaccination. Feline noninjection-site sarcomas (non-FISSs) are less frequently observed in cats and may arise in any anatomic site. This study aimed to determine the differences in the expression of the selected proteins (matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), cyclooxygenase-2 (COX-2), and P-glycoprotein (PGP)) and their correlation with the mitotic count in FISS and non-FISS, in order to characterize their immunohistochemical features. A preliminary study of eleven samples of FISS and eight samples of non-FISS was performed using immunohistochemistry. Among all the tested sarcomas, 80.4% of the tumors were positive for COX-2, 90.2% were positive for MMP-9, and 100% were positive for PGP. The results showed that the expressions of COX-2, MMP-9, and PGP were significantly higher in FISS than in non-FISS (COX-2—p ≤ 0.001; MMP-9—p ≤ 0.05; and PGP—p ≤ 0.05). A Spearman rank correlation analysis showed a moderate negative correlation between the expression of COX-2 and MMP-9 in FISS (r = −0.52). A strong negative correlation between COX-2 and PGP (r = −0.81), a moderate positive correlation between MMP-2 and MMP-9 (r = +0.69), and a moderate negative correlation between MMP-2 and PGP (r = −0.44) were observed in non-FISS. In summary, our study presents the immunohistochemical profile of the proteins involved with inflammation and carcinogenesis in FISS and non-FISS, which can contribute to expanding the knowledge of tumor biology.

show abstract

Immunoexpression and Prognostic Significance of Multidrug Resistance Markers in Feline Mammary Carcinomas

Cited by 2 publications

References 51 publications

Clinical evaluation of the effectiveness of meloxivet in the complex treatment of cats with mammary gland carcinoma

Clinical evaluation of the effectiveness of meloxivet in the complex treatment of cats with mammary gland carcinoma

Comparison of MMP-2, MMP-9, COX-2, and PGP Expression in Feline Injection-Site and Feline Noninjection-Site Sarcomas—Pilot Study

Contact Info

Product

Resources

About